Market Price

81.37 

1.85 2.3%

as of Aug 16 '19

52 Week Range:

74.31 129.59


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 10.93
12.04
15.35
20.24
21.61
25.01
25.05
32.06
42.79
47.87
61.77
growth rate 10.2% 27.5% 31.9% 6.8% 15.7% 0.2% 28.0% 33.5% 11.9% 29.0%
Earnings BIT -72.30
18.77
147.84
299.12
440.67
278.90
538.80
699.00
1,059.20
1,022.40
807.90
growth rate 100.0% 687.6% 102.3% 47.3% -36.7% 93.2% 29.7% 51.5% -3.5% -21.0%
Avg.PE -42.00
151.52
35.59
12.90
9.35
34.48
24.69
10.03
9.62
11.98
9.59
growth rate 100.0% -76.5% -63.8% -27.5% 268.8% -28.4% -59.4% -4.1% 24.5% -20.0%
ROA -5.87
2.02
8.53
14.77
19.36
9.40
17.12
32.03
31.65
16.06
18.76
growth rate 100.0% 322.3% 73.2% 31.1% -51.5% 82.1% 87.1% -1.2% -49.3% 16.8%
ROE -10.65
3.35
13.78
23.78
29.96
14.90
27.19
46.04
41.50
21.14
24.10
growth rate 100.0% 311.3% 72.6% 26.0% -50.3% 82.5% 69.3% -9.9% -49.1% 14.0%
ROIC -9.23
2.82
11.27
22.04
25.04
11.52
24.15
44.19
41.65
18.99
21.44
growth rate 100.0% 299.7% 95.6% 13.6% -54.0% 109.6% 83.0% -5.8% -54.4% 12.9%
Cur. Ratio 5.14
0.98
1.78
2.65
3.78
1.32
1.93
2.89
4.29
3.26
6.39
growth rate -80.9% 81.6% 48.9% 42.6% -65.1% 46.2% 49.7% 48.4% -24.0% 96.0%
Quick Ratio 4.61
0.86
1.63
2.32
3.37
1.18
1.70
2.60
3.81
2.75
5.75
growth rate -81.3% 89.5% 42.3% 45.3% -65.0% 44.1% 52.9% 46.5% -27.8% 109.1%
Leverage 1.72
1.61
1.62
1.60
1.50
1.66
1.52
1.38
1.26
1.37
1.22
growth rate -6.4% 0.6% -1.2% -6.3% 10.7% -8.4% -9.2% -8.7% 8.7% -11.0%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 28.30
50.60
73.70
96.88
116.63
126.30
162.29
192.80
214.50
297.10
175.70
growth rate 78.8% 45.7% 31.5% 20.4% 8.3% 28.5% 18.8% 11.3% 38.5% -40.9%
Acct.Payable 104.48
83.19
92.24
7.00
7.50
8.10
8.40
23.10
growth rate -20.4% 10.9% -92.4% 7.2% 8.0% 3.7% 175.0%
Cur.Assets 297.40
324.50
764.50
562.46
668.47
914.38
957.59
1,275.30
1,424.80
1,447.90
1,768.00
growth rate 9.1% 135.6% -26.4% 18.9% 36.8% 4.7% 33.2% 11.7% 1.6% 22.1%
Total Assets 874.50
1,051.50
1,431.60
1,518.08
1,626.60
2,087.57
1,884.41
2,184.40
2,325.60
2,879.40
3,401.00
growth rate 20.2% 36.2% 6.0% 7.2% 28.3% -9.7% 15.9% 6.5% 23.8% 18.1%
Cash 129.50
100.40
252.20
162.68
154.03
284.26
397.70
831.80
1,023.00
705.10
669.20
growth rate -22.5% 151.2% -35.5% -5.3% 84.6% 39.9% 109.2% 23.0% -31.1% -5.1%
Inventory 14.40
26.40
35.50
45.98
37.25
47.76
66.93
81.30
100.00
107.90
101.00
growth rate 83.3% 34.5% 29.5% -19.0% 28.2% 40.1% 21.5% 23.0% 7.9% -6.4%
Cur.Liabilities 57.70
330.20
428.70
212.58
176.76
687.67
504.31
440.70
332.50
444.70
276.60
growth rate 472.3% 29.8% -50.4% -16.9% 289.1% -26.7% -12.6% -24.6% 33.7% -37.8%
Liabilities 319.20
398.50
547.70
558.71
531.73
783.26
642.05
595.80
474.30
777.60
612.40
growth rate 24.8% 37.4% 2.0% -4.8% 47.3% -18.0% -7.2% -20.4% 64.0% -21.2%
LT Debt 235.00
30.30
0.00
265.63
275.01
3.72
250.00
250.00
growth rate -87.1% -100.0% 3.5% -98.7% 186.2% 0.0%
Equity 555.30
653.00
883.90
948.49
1,083.98
1,259.27
1,242.36
1,588.60
1,851.30
2,101.80
2,788.60
growth rate 17.6% 35.4% 7.3% 14.3% 16.2% -1.3% 27.9% 16.5% 13.5% 32.7%
Common Shares 46.00
56.00
60.00
59.00
53.00
53.00
54.00
0.70
0.70
0.70
0.70
growth rate 21.7% 7.1% -1.7% -10.2% 0.0% 1.9% -98.7% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 124.40
95.40
18.60
35.98
111.91
31.91
47.40
49.80
38.00
86.30
184.40
growth rate -23.3% -80.5% 93.4% 211.0% -71.5% 48.5% 5.1% -23.7% 127.1% 113.7%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -40.43
99.70
211.50
250.20
323.63
425.27
355.30
382.80
643.60
474.20
778.40
growth rate 100.0% 112.1% 18.3% 29.4% 31.4% -16.5% 7.7% 68.1% -26.3% 64.2%
FCF per Share -3.79
0.04
3.24
3.19
3.97
7.38
5.69
8.19
9.30
14.38
9.40
growth rate 100.0% 8,000.0% -1.5% 24.5% 85.9% -22.9% 43.9% 13.6% 54.6% -34.6%
Sale Purchase of Stock -187.60
-171.20
-13.09
53.50
43.30
12.00
44.00
growth rate 0.0% 0.0% 100.0% -19.1% -72.3% 266.7%
FCF -174.00
2.00
193.00
214.00
212.00
393.00
308.00
333.00
600.00
387.00
594.00
growth rate 100.0% 9,550.0% 10.9% -0.9% 85.4% -21.6% 8.1% 80.2% -35.5% 53.5%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 281.50
369.80
592.90
743.18
916.08
1,116.98
1,288.50
1,465.80
1,598.80
1,725.30
1,627.80
growth rate 31.4% 60.3% 25.4% 23.3% 21.9% 15.4% 13.8% 9.1% 7.9% -5.7%
Op.Income -82.10
26.00
171.30
217.24
304.44
174.56
538.80
699.00
1,059.20
1,022.40
807.90
growth rate 100.0% 558.9% 26.8% 40.1% -42.7% 208.7% 29.7% 51.5% -3.5% -21.0%
IBT -83.70
18.80
155.20
299.12
440.67
278.90
525.20
1,044.40
1,060.20
769.50
758.90
growth rate 100.0% 725.5% 92.7% 47.3% -36.7% 88.3% 98.9% 1.5% -27.4% -1.4%
Net Income -49.30
19.50
105.90
217.24
304.44
174.56
340.10
651.60
713.70
417.90
589.20
growth rate 100.0% 443.1% 105.1% 40.1% -42.7% 94.8% 91.6% 9.5% -41.5% 41.0%
EPS -1.08
0.35
1.78
3.67
5.71
3.28
6.28
12.72
15.25
9.31
13.39
growth rate 100.0% 408.6% 106.2% 55.6% -42.6% 91.5% 102.6% 19.9% -39.0% 43.8%
Gross Profit 251.40
324.50
525.20
654.28
796.78
985.86
1,162.60
1,396.80
1,526.10
1,619.60
1,429.10
growth rate 29.1% 61.9% 24.6% 21.8% 23.7% 17.9% 20.1% 9.3% 6.1% -11.8%
R&D 239.20
122.20
165.30
180.02
173.39
299.35
242.50
245.10
147.60
264.60
357.90
growth rate -48.9% 35.3% 8.9% -3.7% 72.7% -19.0% 1.1% -39.8% 79.3% 35.3%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 217.40
152.10
129.00
-655.90
230.20
growth rate -30.0% -15.2% -100.0% 100.0%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 251.30
215.20
175.70
159.80
181.00
growth rate -14.4% -18.4% -9.1% 13.3%
Acct.Payable 216.00
204.80
23.10
139.40
163.90
growth rate -5.2% -88.7% 503.5% 17.6%
Cur.Assets 1,624.20
1,608.70
1,768.00
1,942.50
2,139.80
growth rate -1.0% 9.9% 9.9% 10.2%
Total Assets 3,244.90
3,412.10
3,401.00
3,726.70
3,898.90
growth rate 5.2% -0.3% 9.6% 4.6%
Cash 745.90
656.00
669.20
790.60
881.30
growth rate -12.1% 2.0% 18.1% 11.5%
Inventory 102.70
101.00
101.00
96.20
96.90
growth rate -1.7% 0.0% -4.8% 0.7%
Cur.Liabilities 350.00
372.40
276.60
270.00
463.50
growth rate 6.4% -25.7% -2.4% 71.7%
Liabilities 679.30
719.30
612.40
1,407.70
1,340.50
growth rate 5.9% -14.9% 129.9% -4.8%
LT Debt 250.00
250.00
250.00
1,050.00
800.00
growth rate 0.0% 0.0% 320.0% -23.8%
Equity 2,565.60
2,692.80
2,788.60
2,319.00
2,558.40
growth rate 5.0% 3.6% -16.8% 10.3%
Common Shares 0.70
0.70
0.70
0.70
0.70
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 53.50
41.50
51.80
25.10
20.30
growth rate -22.4% 24.8% -51.5% -19.1%
Cash Dividends
growth rate
Cash From OA 179.80
204.50
118.40
-627.40
132.90
growth rate 13.7% -42.1% -100.0% 100.0%
Sale Purchase of Stock 5.70
growth rate
FCF 126.30
163.00
66.60
-652.50
112.60
growth rate 29.1% -59.1% -100.0% 100.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 444.50
412.70
381.40
362.60
373.60
growth rate -7.2% -7.6% -4.9% 3.0%
Op.Income 217.40
152.10
129.00
-655.90
230.20
growth rate -30.0% -15.2% -100.0% 100.0%
IBT 217.90
140.10
91.90
-650.60
250.40
growth rate -35.7% -34.4% -100.0% 100.0%
Net Income 172.90
106.50
65.30
-494.60
205.10
growth rate -38.4% -38.7% -100.0% 100.0%
EPS
growth rate
Gross Profit 382.80
360.80
349.50
333.50
346.90
growth rate -5.8% -3.1% -4.6% 4.0%
R&D 82.30
101.10
138.80
897.40
77.10
growth rate 22.8% 37.3% 546.5% -91.4%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (80.18)

YOY Growth Grade:

B (67.35)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 7.62 -23.65 12.19
EPS / Growth 30.0% -3.44 -16.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 20.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 17.0% 17.0%
Future PE 2.00 10.67 17.93
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.